Sharemaestro company-news research for Novo Nordisk A/S (NVO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NYSE United States Measured evidence

Company news sentiment

NVO news sentiment

Novo Nordisk A/S

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score51Neutral is 50
Balanced news tone 45/100 evidence confidence 93% direct company focus 31 current stories across 13 publishers
Latest weekly closeUSD 47.26week of 7 Aug 2026
Main news subjectMarket update80/100 share of current news
News data statusHealthy47 duplicate stories removed

Current company news

Balanced news tone

The score uses 31 current company stories from 13 publishers.

Observed headline tone52/100 Published 30-day score51/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race finance.yahoo.com · 13 Aug 2026 18:38

What supports the score

Direct evidence

31 current stories are mapped specifically to NVO.

Source breadth

The score uses 13 publishers rather than depending on one outlet.

Story agreement

The current stories agree at 82/100.

What limits the score

No major limit stands out.

51/100
News scoreBalanced news tone
45/100
Confidencebuilding confidence
93%/100
Company news31 company stories
82/100
Story agreement18/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
17 Jul: 1 stories18 Jul: 1 stories19 Jul: 1 stories21 Jul: 1 stories22 Jul: 1 stories23 Jul: 1 stories24 Jul: 2 stories28 Jul: 2 stories31 Jul: 2 stories02 Aug: 2 stories04 Aug: 1 stories06 Aug: 2 stories07 Aug: 1 stories08 Aug: 2 stories11 Aug: 2 stories12 Aug: 2 stories13 Aug: 5 stories 17 Jul: tone 50, 1 stories18 Jul: tone 43, 1 stories19 Jul: tone 57, 1 stories21 Jul: tone 50, 1 stories22 Jul: tone 57, 1 stories23 Jul: tone 50, 1 stories24 Jul: tone 50, 2 stories28 Jul: tone 43, 2 stories31 Jul: tone 48, 2 stories02 Aug: tone 56, 2 stories04 Aug: tone 50, 1 stories06 Aug: tone 50, 2 stories07 Aug: tone 25, 1 stories08 Aug: tone 50, 2 stories11 Aug: tone 46, 2 stories12 Aug: tone 67, 2 stories13 Aug: tone 52, 5 stories 95505
16 Jul31 Jul14 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence25
1.233 after freshness weighting
Source breadth100
13 independent publishers
Company relevance93
share tied directly to this company
Freshness77
recency-weighted evidence
Agreement82
how closely stories agree
Publisher mix21
less reliance on one publisher

Price and news history

News score and weekly price over 26 weeks

Balanced read

News tone and price action are not far from neutral.

One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb 2026: close 47.92, indexed 100.020 Feb 2026: close 45.84, indexed 95.727 Feb 2026: close 36.2, indexed 75.506 Mar 2026: close 37.29, indexed 77.813 Mar 2026: close 36.69, indexed 76.620 Mar 2026: close 35.31, indexed 73.727 Mar 2026: close 34.84, indexed 72.703 Apr 2026: close 36.98, indexed 77.210 Apr 2026: close 37.52, indexed 78.317 Apr 2026: close 40.52, indexed 84.624 Apr 2026: close 41.17, indexed 85.901 May 2026: close 43.88, indexed 91.608 May 2026: close 46.07, indexed 96.115 May 2026: close 44.74, indexed 93.422 May 2026: close 44.96, indexed 93.829 May 2026: close 45.58, indexed 95.105 Jun 2026: close 42.96, indexed 89.712 Jun 2026: close 43.88, indexed 91.619 Jun 2026: close 43.19, indexed 90.126 Jun 2026: close 48.07, indexed 100.303 Jul 2026: close 50.43, indexed 105.210 Jul 2026: close 49.48, indexed 103.317 Jul 2026: close 50.32, indexed 105.024 Jul 2026: close 48.77, indexed 101.831 Jul 2026: close 47.08, indexed 98.307 Aug 2026: close 47.26, indexed 98.6 26 Jun 2026: news score 50, close 48.07, 14 stories5003 Jul 2026: news score 51, close 50.43, 21 stories5110 Jul 2026: news score 51, close 49.48, 28 stories5117 Jul 2026: news score 51, close 50.32, 32 stories5124 Jul 2026: news score 51, close 48.77, 27 stories5131 Jul 2026: news score 49, close 47.08, 24 stories4907 Aug 2026: news score 47, close 47.26, 26 stories47
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price-1.4%latest close 47.26
News score change-3first to latest comparable week
One-week response+0.4%Price digesting
Fair-value position-41.1%Below fair value
WeekNews scoreCloseWeekly move
07 Aug 202647USD 47.26+0.4%
31 Jul 202649USD 47.08-3.5%
24 Jul 202651USD 48.77-3.1%
17 Jul 202651USD 50.32+1.7%
10 Jul 202651USD 49.48-1.9%
03 Jul 202651USD 50.43+4.9%
26 Jun 202650USD 48.07+11.3%
Value support

News subjects

What is shaping the score

Market update
Market update5017 stories · 55%
Earnings617 stories · 23%
Regulatory and legal323 stories · 10%
Capital return652 stories · 6%
Analyst action442 stories · 6%

Source mix

Where the evidence comes from

21/100 independence
finance.yahoo.com5211 stories · 35%
Seeking Alpha353 stories · 10%
foreignpolicyjournal.com633 stories · 10%
MT Newswires462 stories · 6%
simplywall.st502 stories · 6%
Market source502 stories · 6%
The Globe and Mail651 stories · 3%

Recurring subjects

Subjects appearing most often

Current evidence
Pharma5Earnings5EARNINGS4Healthcare3Diabetes3PHARMA2Obesity2Lawsuit2Fourth Quarter2DIABETES2

Earlier readings

How the score has changed

40 comparable readings · 54 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+450 to 54 · Strengthening
Observed range47–5450 is the neutral baseline
Evidence depth60stories at latest stored reading · +59
Confidence57/100Measured · +31
20 Jun50 neutral14 Aug 00:16
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
14 Aug 00:1654+057/100 (-1)60 (0)Measured
13 Aug 23:5954+458/100 (+7)60 (+9)Measured
12 Aug 23:5950+151/100 (0)51 (+4)Measured
11 Aug 23:5949-151/100 (+1)47 (+5)Measured
10 Aug 23:5950+250/100 (+11)42 (+12)Measured
09 Aug 23:5948+039/100 (-1)30 (0)Measured
08 Aug 23:5948+140/100 (+3)30 (+4)Measured
07 Aug 23:5947-337/100 (+10)26 (+2)Provisional

Source headlines

The news behind the score

Showing 1-30 of 31

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#150Tone
finance.yahoo.comDirect company coverageStored article

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment

Clinical TrialsObesityPharmaValuation
Published
13 Aug 2026 18:38
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 3.9% · 0.1d old
Duplicates
3 consolidated
#235Tone
finance.yahoo.comDirect company coverageStored article

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy gap consumers may perceive between Wegovy and Zepbound. Is LLY fairly valued? Test your thesis with our free DCF calculator. Novo Nordisk develops treatments for diabetes, obesity and other chronic disea

AdvertisingLawsuitMarket ShareObesity TreatmentsPharma
Published
13 Aug 2026 17:32
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 13.9% · 0.1d old
Duplicates
15 consolidated
#376Tone
finance.yahoo.comDirect company coverageStored article

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley

EarningsEarnings GrowthHealthcarePharmaWeight Loss
Published
13 Aug 2026 17:20
News subject
Earnings
Why this score
Beat expectations
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Medium · 13.3% · 0.1d old
Duplicates
15 consolidated
#431Tone
finance.yahoo.comDirect company coverageStored article

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an

Balance SheetHealthcareObesity CarePharmaceuticalsPricing PressureRevenue Growth
Published
13 Aug 2026 15:12
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 12.2% · 0.2d old
Duplicates
63 consolidated
#566Tone
finance.yahoo.comDirect company coverageStored article

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite NVO delivering a better-than-expected second-quarter 2026 performance. NVO's reported second-quarter sales rose 3% to $12.21 billion (DKK 78.5 billion) at constant exchange rates (CER). More importantly, its key GLP-1 brands showed signs of slowing. Ozempic generated $4.88 billion (DKK 31.4 billion) in repo

CompetitionDiabetesFourth QuarterGlp 1ObesityPharma
Published
13 Aug 2026 14:26
News subject
Earnings
Why this score
Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 12.1% · 0.2d old
Duplicates
127 consolidated
#645Tone
finance.yahoo.comDirect company coverageStored article

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales

DOWNGRADEDowngradeEARNINGSEarningsPHARMAPharma
Published
12 Aug 2026 17:29
News subject
Analyst action
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 4.6% · 1.1d old
Duplicates
383 consolidated
#775Tone
finance.yahoo.comDirect company coverageStored article

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo

DIABETESDiabetesEARNINGSEarningsFOURTH QUARTERFourth Quarter
Published
12 Aug 2026 15:10
News subject
Earnings
Why this score
Beat expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 13.4% · 1.2d old
Duplicates
383 consolidated
#850Tone
finance.yahoo.comDirect company coverageStored article

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinica

AICLOUDCloudEARNINGSEarnings
Published
11 Aug 2026 12:38
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Low · 3.4% · 2.3d old
Duplicates
767 consolidated
#943Tone
nasdaq.comDirect company coverageStored article

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised. There are 10 different analyst

ETFSEtfsMARKETSMarketsPRICE TARGETPRICE-TARGET
Published
11 Aug 2026 11:43
News subject
Analyst action
Why this score
Negative financial language
Company focus
Company discussed · 86%
How it is used
Direct company coverage
Weighted influence
Low · 4.2% · 2.4d old
Duplicates
384 consolidated
#1050Tone
finance.yahoo.comDirect company coverageStored article

Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and

BALANCE SHEETBalance SheetHEALTHCAREHealthcarePATENT-ENFORCEMENTPHARMA
Published
08 Aug 2026 23:10
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Low · 0.6% · 4.9d old
Duplicates
767 consolidated
#1150Tone
finance.yahoo.comDirect company coverageStored article

Novo Nordisk A/S Q2 Earnings Call Highlights

Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower realized prices, manufacturing costs and currency effects reduced the adjusted gross margin to 78.2% from 82.7%. Oral Wegovy drove obesity-treatment momentum. The U.S. pill surpassed 5 million prescriptions and captured about 90% of the oral obesity-drug market, while roughly 80% of users were new to GLP-1 treatments; internatio

CARDIOVASCULARCardiovascularDIABETESDiabetesEARNINGSEarnings
Published
08 Aug 2026 22:03
News subject
Earnings
Why this score
Guidance raised, Deteriorating financial comparison
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Low · 3.4% · 4.9d old
Duplicates
767 consolidated
#1225Tone
finance.yahoo.comDirect company coverageStored article

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, the case was filed by Strive Specialties, which claimed the drugmakers unfairly limited access to compounded GLP-1 weight-loss drugs through exclusive telehealth partnerships. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator

ANTITRUSTAntitrustLAWSUITLawsuitOBESITY-DRUGSObesity Drugs
Published
07 Aug 2026 19:52
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Medium · 8.1% · 6.0d old
Duplicates
767 consolidated
#1350Tone
The Wall Street JournalDirect company coverageScored from headlineSource lookup

How Novo Nordisk’s CEO Says He Is Shifting the Company’s Perspective

Published
06 Aug 2026 12:52
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.6% · 7.3d old
Duplicates
9 consolidated
#1450Tone
simplywall.stDirect company coverageScored from headlineSource lookup

Novo Nordisk (NYSE:NVO) Stock May Be Below Fair Value On ZEUS Trial Fallout

Published
06 Aug 2026 06:08
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.3% · 7.6d old
Duplicates
9 consolidated
#1650Tone
Market sourceDirect company coverageScored from headlineSource lookup

Novo Nordisk (NVO) Trial Setback Hits Sentiment, Is The Stock Still Cheap?

Published
02 Aug 2026 16:04
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 11.2d old
Duplicates
9 consolidated
#1950Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup

Novo Nordisk Stock: Too Late For A Great Opportunity (NYSE:NVO)

Published
31 Jul 2026 11:12
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 13.4d old
Duplicates
9 consolidated
#2350Tone
simplywall.stDirect company coverageScored from headlineSource lookup

Novo Nordisk (NVO) Faces A Fair Value Debate, Is The Stock A Bargain?

Published
24 Jul 2026 04:11
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 20.7d old
Duplicates
9 consolidated
#2450Tone
Market sourceDirect company coverageScored from headlineSource lookup

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

Published
23 Jul 2026 09:35
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 21.4d old
Duplicates
9 consolidated
#2650Tone
Stock TitanDirect company coverageScored from headlineSource lookup

Novo Nordisk (NYSE: NVO) reports 24,959,179 shares repurchased in 2026 programme

Published
21 Jul 2026 11:00
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 23.4d old
Duplicates
9 consolidated
#2950Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup

Novo Nordisk: The Oral Wegovy Promise (NYSE:NVO)

Published
17 Jul 2026 17:29
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 27.1d old
Duplicates
18 consolidated

Earlier company news

NVO news archive

Showing 1-27 of 27 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Provider matches checked

Provider mentions not used in the score

37 not scored

A news provider linked these stories to NVO, but the headline and available text are not mainly about Novo Nordisk A/S. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of NVO sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context